At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.